Patents Assigned to Regeneron Pharmaceuticals, Inc.
  • Patent number: 11988668
    Abstract: Methods for producing high concentration protein formulations having high stability are provided. Assays for selecting proteins and formulation conditions that have high self-repulsive attributes are used as an early step in the manufacturing process. Specifically, a protein concentration-dependent self-interaction nanoparticle spectroscopy method is employed as a protein colloidal interaction assay.
    Type: Grant
    Filed: July 20, 2022
    Date of Patent: May 21, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Michael Marlow, Michael Sennett, Michael Schneider
  • Patent number: 11986511
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: May 21, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: George D. Yancopoulos
  • Publication number: 20240158515
    Abstract: The present invention provides antibodies that bind specifically to FGFR3 and methods for treating or preventing cancer, such as bladder cancer.
    Type: Application
    Filed: November 14, 2023
    Publication date: May 16, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Yan YANG, Christopher DALY, William OLSON, Tammy T. HUANG, Drew DUDGEON, Robert BABB
  • Patent number: 11981913
    Abstract: Methods of determining the stoichiometry of a viral capsid and/or determining the heterogeneity of protein components in a viral capsid.
    Type: Grant
    Filed: May 17, 2022
    Date of Patent: May 14, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Shunhai Wang
  • Publication number: 20240150165
    Abstract: A system for dispensing biopharmaceutical materials, the system including: a plurality of containers, wherein each of the plurality of containers comprises a screw-on cap having a low temperature silicone stopper; a distribution manifold connected to the plurality of containers, wherein the distribution manifold comprises a plurality of distribution conduits and a plurality of discharge conduits and wherein the distribution conduits and the discharge conduits are in fluid communication with each other; a bulk reservoir for holding the biopharmaceutical materials; and a filter assembly positioned between the bulk reservoir and the distribution manifold.
    Type: Application
    Filed: November 7, 2023
    Publication date: May 9, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventor: Tikiri Jean DISSANAYAKE
  • Publication number: 20240147971
    Abstract: Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent Tmprss gene, such as an endogenous rodent Tmprss2, Tmprss4, or Tmprss11d gene.
    Type: Application
    Filed: January 16, 2024
    Publication date: May 9, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Lisa Purcell, Alexander O. Mujica, Yajun Tang
  • Publication number: 20240152673
    Abstract: A method of evaluating a mixing protocol may include identifying a domain of mixing protocol parameters for a multivariate model and identifying an evaluation criterion for the multivariate model. The method may further include using predictor screening to determine a set of mixing protocol parameters from the domain of mixing protocol parameters, wherein the set of mixing protocol parameters account for a threshold observed variance in the evaluation criterion. The method may include generating the multivariate model, wherein the multivariate model relates the set of mixing protocol parameters to the evaluation criterion. The method may also include generating an estimated value of the evaluation criterion for the mixing protocol, using the multivariate model.
    Type: Application
    Filed: November 7, 2023
    Publication date: May 9, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Ross KENYON, Saber MEAMARDOOST, Thomas MADDEN
  • Publication number: 20240153587
    Abstract: Methods and systems are described for optimizing search results through querying a plurality of databases according to false discovery, random hit rates are presented herein. Methods and systems adapted to assigning a putative source to a de novo peptide sequence and/or creating a workflow for performing said assignment are presented herein.
    Type: Application
    Filed: March 11, 2022
    Publication date: May 9, 2024
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lili Blumenberg, Kamil Cygan, Ankur Dhanik, Robert Salzler
  • Patent number: 11977081
    Abstract: The present invention provides ELISA-based methods for detecting and/or quantifying ANGPTL8 in biological samples using anti-ANGPTL8 antibodies.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 7, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy
  • Patent number: 11975045
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: May 7, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: George Yancopoulos
  • Publication number: 20240138384
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Application
    Filed: January 16, 2024
    Publication date: May 2, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Patent number: 11971393
    Abstract: Embodiments of the present disclosure may assist in managing, storing, using, and re-using dedicated chromatography column bed supports. For example, devices and systems disclosed herein may include reusable cases for storing dedicated column bed supports when the column bed supports are not in use. Such cases may include one or more dividers and inserts configured to fit column bed supports, and may be designed and built specifically to ensure efficient, secure storage of column bed supports while minimizing risk of damaging or contaminating them. Methods disclosed herein may include performing a particular chromatography operation in a column, removing the column bed supports from the column, storing the column bed supports in a column bed support storage case, and installing another set of column bed supports in the column for another chromatography operation.
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: April 30, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kevin Kent, Joseph Gallea, Benjamin Binga
  • Patent number: 11970724
    Abstract: The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest.
    Type: Grant
    Filed: July 8, 2021
    Date of Patent: April 30, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shadia Abike Oshodi, Amy S. Johnson, Shawn M. Lawrence
  • Publication number: 20240131175
    Abstract: Provided herein are methods and compositions for site-specific conjugation of antibodies in the presence of a transglutaminase.
    Type: Application
    Filed: August 23, 2023
    Publication date: April 25, 2024
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Amy HAN, William OLSON, Christopher D'SOUZA
  • Patent number: 11965020
    Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
    Type: Grant
    Filed: May 17, 2023
    Date of Patent: April 23, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
  • Patent number: 11963521
    Abstract: Non-human animals comprising a human or humanized IL-4 and/or IL-4R? nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous IL-4 gene and/or IL-4R? gene with a human IL-4 gene and/or IL-4R? gene in whole or in part, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized IL-4 gene under control of non-human IL-4 regulatory elements is also provided, including non-human animals that have a replacement of non-human IL-4-encoding sequence with human IL-4-encoding sequence at an endogenous non-human IL-4 locus. Non-human animals comprising a human or humanized IL-4R? gene under control of non-human IL-4R? regulatory elements is also provided, including non-human animals that have a replacement of non-human IL-4R?-encoding sequence with human or humanized IL-4R?-encoding sequence at an endogenous non-human C IL-4R? locus.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: April 23, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Li-Hsien Wang, Yingzi Xue, Andrew J. Murphy, Sean Stevens
  • Patent number: 11965161
    Abstract: Provided herein are methods and compositions related to the treatment or prevention of cancer (e.g., by targeting a tumor in a subject with cancer) by administering to a subject an agent that inhibits autophagy. In certain aspects, provided herein are methods of compositions related to methods of sensitizing cancer cells to tumor necrosis factor-alpha (TNF-?) mediated killing by contacting the cells or administering the agent that inhibits autophagy.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: April 23, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Tara Young, Christopher Daly, Gavin Thurston
  • Patent number: 11965153
    Abstract: A method of controlling a bioreactor system includes providing a cell culture in a bioreactor, wherein conditions in the bioreactor enable the cell culture to produce a protein of interest (POI), measuring process parameters (PPs) of the culture within the bioreactor by RAMAN, wherein the process parameters are selected from the group consisting of nutrient concentration, viable cell concentration, and protein attributes, measuring a predetermined weight of the bioreactor with the cell culture, removing cell-free spent media from the cell culture using a first output conduit at a first specified rate, removing cells from the cell culture using a second output conduit at a second specified rate, and introducing one or both of fresh media or nutrients into the cell culture using an input conduit at a third specified rate.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: April 23, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Matthew Angelini, Ashley Witmer, Anthony Debiase
  • Patent number: D1024321
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: April 23, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christopher Hunter, Connor Block
  • Patent number: D1028224
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: May 21, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christopher Hunter, Connor Block